Summit Therapeutics Share Discussion Threads

[abergele] 13/2/2017 19:44

nice rise later on.gla tomoz.

[hugus maximus] 13/2/2017 18:39

Interesting that this past week or so the NASDAQ has been sitting below the AIM share price

At least whilst we're waiting for significant news the share price seems to be holding up well above where most of us LTH's bought. Still wondering if there's a leaching of SRPT shareholders over to Summit as SRPT hasn't been holding up too well.

I wonder if interest in Summit may one day prop up Sarepta? Will European rights for a successful SMTC1100 P2 drug do enough to restore Sarepta's Market Cap?

[chrisatrdg] 13/2/2017 11:39

13 Feb 2017 BIO CEO & Investor Conference (New York) - Erik Ostrowski
CFO - webcast 3.30 UK time today



Edit 1: Slide show to be shortly available not sure that there was any new news but confident presentation but no question & answer session.

Edit 2: NASDAQ on the up supporting AIM maybe the message is getting through.

[luminoso] 10/2/2017 22:54

Would I be right in thinking that this 'old steroid' is really just a palliative, while EZT will be something of an enabler - ie enabling sufferers to lead a more normal life with the disease - rather than a cure ?
I seem to remember Kay Davies saying in an interview that utrophin up regulation was not a cure for DMD.

[waterloo01] 10/2/2017 14:35

The bar gets even lower! With a little Chutzpah, might we get earlier approvals?

This has been on the market in Europe for years and from my reading of the boards, many US patients are on it already. Not a competitor as not a cure.

[freemoney1] 09/2/2017 20:35

Yes an article for short - medium term traders to turn a quick profit. For LTH with more confidence in the science the upside is potentially far greater! GLA

[chrisatrdg] 09/2/2017 14:17

Hi waterloo01 you just beat me to it - the article makes for a good read for any new investor & a reminder as to why we are invested but with a de-risking warning.Best article I have seen for some time.

The title is:

Play The Runup On Summit Therapeutics

[waterloo01] 09/2/2017 14:07

To conclude, I believe the runup in share price could continue into the 24 week biopsy data in the PhaseOut DMD trial. Investors establishing a position in the near term could see a 50% return or more. Data for the phase 2 trial of ridinilazole could also provide material upside, although I believe Wall Street is focused on ezutromid as the primary value driver.

[football] 07/2/2017 23:39

maybe a reverse take over by summit








only joking

;)

[luminoso] 07/2/2017 22:07

Quite. Who would want to buy them out ?

[hugus maximus] 07/2/2017 20:21

Looks to be a load of tosh!

[hugus maximus] 07/2/2017 16:27

What's up on planet Sarepta?

"Sarepta Perks Up 2% On Buyout Speculation

Feb. 7, 2017 11:07 AM ET|About: Sarepta Therapeutics, ... (SRPT)|By: Douglas W. House, SA News Editor

Sarepta Therapeutics (SRPT +2.3%) moves up on light volume amidst speculation on social media that a buyout may be in the offing. The company supposedly canceled its presentation at Cowen's investor conference but Cowen confirmed its participation."

[freemoney1] 06/2/2017 15:19

Spotted that too Waterloo... this article is good...
If we can get Ridinilazole to market quicker than two length P3's that'll be a huge value inflection point at this stage!

"The pharmaceutical sector welcomed Trump’s pledge to reduce regulations and make the process of getting new drugs to market easier. “We’re also gonna be streamlining the process so that from your standpoint, when you have a drug, you can actually get it approved if it works instead of waiting for many, many years,” Trump said. He will soon name an FDA commissioner who will be “streamlining” the Food and Drug Administration, a move that raises concerns about the quality, effectiveness, and safety of new medicines."

[waterloo01] 06/2/2017 14:06

I see Jim O'neal is one of the names touted for the new head of FDA. We certainly know where he stands on antibiotics and incentives/penalties.

[vatnabrekk] 05/2/2017 16:28

It's certainly looking good. I think it's just a case of sitting tight for now, and perhaps topping up on dips during the next 12 months or so.

[waterloo01] 04/2/2017 17:53

All depends on ones timelines. It's already taken years to get to this point, so much of the risk has already been taken. If the FDA does move towards Trumps view then it's also ripe for an early approval (as safety isn't an issue and it will save lives on day one).

Glyn made a bold statement in the proactive piece, saying it's almost sure to replicate what was seen in the phase 2, and as such it's highly unlikely it will fail. Not often one can say that! I note Glyn made reference to global trials, so the grant funder or partner will likely be 'global' players, thankfully not equity.

Given the potential size of the market, if approved for 1st and 2nd line treatment as they have stated, will be quick to build, as they have some price advantages and the economic advantages is one of the endpoints. They should also price it low, but that will be our 'partners' choice one suspects.

HC Wainwright note suggest peak sales around £930m (sterling).

[vatnabrekk] 04/2/2017 15:52

OK, thanks waterloo. So not a "near-term" thing, then!

[waterloo01] 04/2/2017 14:25

vatnabrekk, probably about 2 years to get results, so if start 1st H 18, could be approved and on the market 2021?

[vatnabrekk] 04/2/2017 11:45

Assuming phase 3 starts sometime in H1 2018, does anyone have an indication how long the trial might take?

[football] 03/2/2017 13:12

What We’re Looking For From Summit Therapeutics PLC (ADR) (NASDAQ:SMMT)
By Mark Collins - February 2, 2017

[hugus maximus] 03/2/2017 12:55

<"The CDI trials should initiate at some point during the first half of 2018. During this period, we’re looking for any suggestion that the company can find a big name partner (in a similar fashion as its DMD drug) for Ridinilazole.">

Don't be wrong footed by the slightly ambiguous grammar in this article. Summit will not only be looking for a 3rd party "during this period" (2018)... it being open for discussions with a 3rd party any time between then and now.

This article is mainly about C Diff and after the announcement that P3 trials have been set-up for 2018, the next related major positive share move may be the announcement of good results for last years P2 comparison trial with current best gold standard Fidaxomicin.

Positive P2 Fidaxomicin results could see the next share price gain here and a major 3rd party investment.

Edit - what is the anticipated schedule on this?

[waterloo01] 02/2/2017 16:58

Decent article,. (via freemoney on lse)

"Just as importantly, and as some reading will already be aware, Summit scored a partnership deal for its DMD drug last year, which brought with it certain financial benefits. Benefits that, for the foreseeable future, at least, should cover the company’s costs, and free up management to focus on raising, and we’re quoting here, non dilutive equity to fund the CDI phase 3.

So what is next?

The CDI trials should initiate at some point during the first half of 2018. During this period, we’re looking for any suggestion that the company can find a big name partner (in a similar fashion as its DMD drug) for Ridinilazole.

If it doesn’t, it’s not too big a deal, but if it does, there’s some immediate upside in the announcement, and its aftermath."

[chrisatrdg] 02/2/2017 15:49

Just out Glyn Edwards C-Diff:

Summit Therapeutics aiming to 'make a big impact' with new drug Ridinilazole




X proactive X investors

[luminoso] 01/2/2017 20:44

Great posts, Waterloo. Nasdaq action very encouraging as there has not been a flicker of traders selling the spike, at least at this point in time. Think we really might be on the move now, because all your comments on a likely buyout one day will be what the markets will also be thinking....hopefully an institution or three.